reagila
gedeon richter - cariprazinhydrochlorid - skizofreni - psykoleptika - reagila er indiceret til behandling af skizofreni hos voksne patienter.
pelmeg
mundipharma corporation (ireland) limited - pegfilgrastim - neutropeni - immunostimulants, - til at reducere varigheden af neutropeni og forekomsten af febril neutropeni på grund af kemoterapi.
verzenios
eli lilly nederland b.v. - abemaciclib - bryst neoplasmer - antineoplastiske midler - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.
emgality
eli lilly nederland b.v. - galcanezumab - migræneforstyrrelser - analgesics, galcanezumab - emgality er indiceret til forebyggelse af migræne hos voksne, der har mindst 4 migræne dage per måned.
efavirenz/emtricitabine/tenofovir disoproxil "glenmark" 600+200+245 mg filmovertrukne tabletter
glenmark arzneimittel gmbh - efavirenz, emtricitabin, tenofovirdisoproxilfumarat - filmovertrukne tabletter - 600+200+245 mg
cegfila (previously pegfilgrastim mundipharma)
mundipharma corporation (ireland) limited - pegfilgrastim - neutropeni - immunostimulants, - reduktion i varigheden af neutropeni og forekomst af febril neutropeni hos voksne patienter behandlet med cytotoksisk kemoterapi for malignitet (med undtagelse af kronisk myeloid leukæmi og myelodysplastisk syndromer).
baqsimi
eli lilly nederland b.v. - glucagon - diabetes mellitus - pancreas hormoner, hormoner glycogenolytic - baqsimi er indiceret til behandling af alvorlig hypoglykæmi hos voksne, unge og børn i alderen 4 år og derover med diabetes mellitus.
lyumjev (previously liumjev)
eli lilly nederland b.v. - insulin lispro - diabetes mellitus - narkotika anvendt i diabetes - behandling af diabetes mellitus hos voksne, unge og børn i alderen 1 år og derover. behandling af diabetes mellitus hos voksne.
retsevmo
eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - antineoplastiske midler - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.
mounjaro
eli lilly nederland b.v. - tirzepatide - diabetes mellitus, type 2 - narkotika anvendt i diabetes - mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications- in addition to other medicinal products for the treatment of diabetes. for study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4. 4, 4. 5 og 5.